UroGen Pharma Ltd. (NASDAQ:URGN) Insider Sells 5,153 Shares of Stock

UroGen Pharma Ltd. (NASDAQ:URGN) insider Mark Schoenberg sold 5,153 shares of UroGen Pharma stock in a transaction on Monday, June 10th. The shares were sold at an average price of $13.08, for a total value of $67,401.24. Following the sale, the insider now directly owns 144,284 shares in the company, valued at approximately $1,887,234.72. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Mark Schoenberg also recently made the following trade(s):

• On Monday, March 18th, Mark Schoenberg sold 12,000 shares of UroGen Pharma stock. The shares were sold at an average price of $14.05, for a total value of $168,600.00.

UroGen Pharma Stock Up 2.5 %

Shares of UroGen Pharma stock traded up $0.32 on Tuesday, hitting $13.09. 498,939 shares of the company traded hands, compared to its average volume of 324,074. UroGen Pharma Ltd. has a 12-month low of $8.69 and a 12-month high of $24.13. The company has a 50-day moving average price of $13.61 and a 200 day moving average price of $14.97. The company has a market cap of $306.96 million, a PE ratio of -3.81 and a beta of 1.08.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.04). The firm had revenue of $18.78 million during the quarter, compared to the consensus estimate of $20.73 million. Equities research analysts anticipate that UroGen Pharma Ltd. will post -3.6 EPS for the current year.

Institutional Trading of UroGen Pharma

A number of institutional investors have recently added to or reduced their stakes in the business. Tidal Investments LLC acquired a new position in shares of UroGen Pharma during the 1st quarter worth $425,000. Price T Rowe Associates Inc. MD acquired a new stake in shares of UroGen Pharma in the first quarter worth about $4,008,000. Vanguard Group Inc. boosted its stake in shares of UroGen Pharma by 14.3% during the 1st quarter. Vanguard Group Inc. now owns 194,966 shares of the company’s stock worth $2,924,000 after acquiring an additional 24,367 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in shares of UroGen Pharma by 73.1% during the 1st quarter. BNP Paribas Financial Markets now owns 39,795 shares of the company’s stock valued at $597,000 after acquiring an additional 16,799 shares during the last quarter. Finally, Oak Ridge Investments LLC bought a new position in shares of UroGen Pharma in the 1st quarter valued at approximately $918,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on URGN. Oppenheimer lowered their price objective on shares of UroGen Pharma from $34.00 to $32.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 14th. HC Wainwright restated a “buy” rating and issued a $54.00 price target on shares of UroGen Pharma in a research report on Tuesday, May 14th.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.